loading
前日終値:
$13.17
開ける:
$13.11
24時間の取引高:
937.17K
Relative Volume:
0.55
時価総額:
$41.58B
収益:
$30.27B
当期純損益:
$1.93B
株価収益率:
29.66
EPS:
0.444
ネットキャッシュフロー:
$3.45B
1週間 パフォーマンス:
-1.42%
1か月 パフォーマンス:
-1.57%
6か月 パフォーマンス:
+2.25%
1年 パフォーマンス:
-6.26%
1日の値動き範囲:
Value
$13.09
$13.19
1週間の範囲:
Value
$12.98
$13.37
52週間の値動き範囲:
Value
$12.57
$15.08

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name
名前
Takeda Pharmaceutical Co Adr
Name
セクター
Healthcare (1177)
Name
電話
-
Name
住所
-
Name
職員
49,281
Name
Twitter
@takedapharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
TAK's Discussions on Twitter

TAK を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.16 41.58B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
164.70 74.13B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.745 43.93B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
22.25 25.41B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
12.38 14.57B 15.05B -883.30M 1.89B -0.74

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-03-16 アップグレード BofA Securities Neutral → Buy
2022-07-19 アップグレード Cowen Market Perform → Outperform
2021-10-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-04-19 ダウングレード JP Morgan Overweight → Neutral
2019-11-01 開始されました Cowen Market Perform
2019-08-15 ダウングレード Daiwa Securities Outperform → Neutral
すべてを表示

Takeda Pharmaceutical Co Adr (TAK) 最新ニュース

pulisher
Dec 23, 2024

Burkitt Lymphoma Global Clinical Trials Review 2024: Clinical Trials by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.

Dec 23, 2024
pulisher
Dec 16, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Dec 16, 2024
pulisher
Nov 30, 2024

Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 30, 2024
pulisher
Nov 28, 2024

Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow

Nov 28, 2024
pulisher
Nov 22, 2024

Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register

Nov 22, 2024
pulisher
Nov 21, 2024

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN

Nov 21, 2024
pulisher
Nov 20, 2024

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow

Nov 20, 2024
pulisher
Nov 20, 2024

Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 20, 2024
pulisher
Nov 20, 2024

Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 20, 2024
pulisher
Nov 18, 2024

Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 18, 2024

UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 18, 2024

South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Nov 18, 2024
pulisher
Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 05, 2024

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN

Nov 05, 2024
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia

Nov 03, 2024
pulisher
Nov 03, 2024

Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa

Nov 03, 2024
pulisher
Nov 02, 2024

Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register

Nov 02, 2024
pulisher
Nov 02, 2024

What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register

Nov 02, 2024
pulisher
Oct 21, 2024

Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 21, 2024
pulisher
Oct 21, 2024

Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 21, 2024
pulisher
Oct 16, 2024

Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register

Oct 16, 2024
pulisher
Oct 15, 2024

Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily

Oct 15, 2024
pulisher
Oct 11, 2024

Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 11, 2024

Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024

Takeda Pharmaceutical Co Adr (TAK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_specialty_generic HLN
$9.745
price up icon 0.31%
$22.25
price up icon 0.95%
$12.15
price down icon 2.64%
$137.23
price up icon 0.19%
drug_manufacturers_specialty_generic RDY
$15.66
price up icon 1.11%
大文字化:     |  ボリューム (24 時間):